Afatinib

Therapeutic indications

Afatinib is indicated for:

Non-small cell lung cancer (NSCLC) with activating EGFR mutation

Population group: both men and women, only adults (18 years old or older)

Afatinib as monotherapy is indicated for the treatment of epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

40-50 mg once daily

Non-small cell lung cancer (NSCLC) of squamous histology

Population group: both men and women, only adults (18 years old or older)

Afatinib as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

40-50 mg once daily

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: GIOTRIF Film-coated tablets
< Previous: Overview
Next: Precautions >